Genenta Science S.p.A.

5.75-0.3499-5.74%Vol 1.20K1Y Perf -13.35%
Mar 30th, 2023 12:49 DELAYED
BID5.75 ASK6.10
Open5.70 Previous Close6.10
Pre-Market- After-Market-
 - -  - -%
Target Price
20.75 
Analyst Rating
Strong Buy 1.00
Potential %
260.87 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
34.07 
Earnings Rating
Market Cap104.74M 
Earnings Date
-
Alpha0.07 Standard Deviation0.26
Beta3.31 

Today's Price Range

5.705.75

52W Range

3.909.33

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.88%
1 Month
-9.45%
3 Months
4.55%
6 Months
15.46%
1 Year
-13.35%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GNTA5.75-0.3499-5.74
AAPL164.902.54001.56
GOOG104.002.68002.65
MSFT289.275.22001.84
XOM109.660.17000.16
WFC37.380.00000.00
JNJ155.001.57001.02
FB196.640.99000.51
GE95.601.55001.65
JPM130.311.56001.21
 
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.20K
Shares Outstanding18.22K
Shares Float18.22M
Trades Count7
Dollar Volume6.89K
Avg. Volume4.76K
Avg. Weekly Volume5.77K
Avg. Monthly Volume4.42K
Avg. Quarterly Volume4.08K

Genenta Science S.p.A. (NASDAQ: GNTA) stock closed at 5.75 per share at the end of the most recent trading day (a -5.74% change compared to the prior day closing price) with a volume of 1.20K shares and market capitalization of 104.74M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Genenta Science S.p.A. CEO is Pierluigi Paracchi.

The one-year performance of Genenta Science S.p.A. stock is -13.35%, while year-to-date (YTD) performance is 4.55%. GNTA stock has a five-year performance of %. Its 52-week range is between 3.9 and 9.33, which gives GNTA stock a 52-week price range ratio of 34.07%

Genenta Science S.p.A. currently has a PE ratio of -26.30, a price-to-book (PB) ratio of 2.68, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -13.94%, a ROC of -14.79% and a ROE of -14.79%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Genenta Science S.p.A., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Genenta Science S.p.A.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Genenta Science S.p.A. is Strong Buy (1), with a target price of $20.75, which is +260.87% compared to the current price. The earnings rating for Genenta Science S.p.A. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Genenta Science S.p.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Genenta Science S.p.A. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.62, ATR14 : 0.36, CCI20 : -123.74, Chaikin Money Flow : -0.26, MACD : -0.17, Money Flow Index : 36.29, ROC : -14.18, RSI : 40.98, STOCH (14,3) : 10.96, STOCH RSI : 0.48, UO : 38.14, Williams %R : -89.04), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Genenta Science S.p.A. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Genenta Science S.p.A.

Genenta Science SPA is a clinical-stage biotechnology company pioneering the development of lentivirus-based first-in-class gene and cell therapies in cancer.

CEO: Pierluigi Paracchi

Telephone: +39 226436639

Address: Via Olgettina No. 58, Milan 20132, , IT

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

54%46%

Bearish Bullish

52%48%


News

Stocktwits